Drug
Tak 164
Tak 164: highest development phase Phase 1, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-164 NCT03449030 | Phase 1 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies |
Latest
No recent events.
Follow Tak 164 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.